Payment overview · 2025
General Payments
$302.67
13 reported records · 7 companies
Healthcare provider profile · identity verified
John Floyd Merrill, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · CLARKSTON, WA · NPI 1992152326
Verified facts
What the public records show
CMS Open Payments records show John Floyd Merrill, D.O. received $302.67 in general payments during 2025 across 13 reported records.
AstraZeneca Pharmaceuticals LP accounted for 45.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $138.95 | 45.9% | 5 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.91 | 12.2% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $32.90 | 10.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.54 | 9.8% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $27.76 | 9.2% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $19.77 | 6.5% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.84 | 5.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $302.67 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $117.04 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $83.76 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $61.85 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $36.91 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $32.90 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $29.54 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $29.54 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $27.76 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $19.77 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $16.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
119 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 694 | 187 |
| Amlodipine Besylate | Amlodipine Besylate | 532 | 149 |
| Atorvastatin Calcium | Atorvastatin Calcium | 461 | 132 |
| Levothyroxine Sodium | Levothyroxine Sodium | 460 | 113 |
| Omeprazole | Omeprazole | 417 | 131 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 412 | 115 |
| Hydrochlorothiazide | Hydrochlorothiazide | 359 | 103 |
| Lisinopril | Lisinopril | 303 | 80 |
| Potassium Chloride | Potassium Chloride | 271 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 268 | 76 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 245 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 235 | 74 |
| Gabapentin | Gabapentin | 218 | 59 |
| Simvastatin | Simvastatin | 210 | 51 |
| Metformin Hcl | Metformin Hcl | 185 | 49 |
| Carvedilol | Carvedilol | 183 | 48 |
| Metformin Hcl Er | Metformin Hcl | 181 | 50 |
| Sertraline Hcl | Sertraline Hcl | 180 | 50 |
| Trazodone Hcl | Trazodone Hcl | 155 | 45 |
| Furosemide | Furosemide | 149 | 44 |
| Allopurinol | Allopurinol | 120 | 37 |
| Eliquis | Apixaban | 119 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 118 | 34 |
| Tramadol Hcl | Tramadol Hcl | 115 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 39 |
| Spironolactone | Spironolactone | 108 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 29 |
| Telmisartan | Telmisartan | 82 | 23 |
| Estradiol | Estradiol | 71 | 22 |
| Glipizide | Glipizide | 70 | 22 |
| Donepezil Hcl | Donepezil Hcl | 69 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 66 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 66 | 21 |
| Lorazepam | Lorazepam | 64 | 13 |
| Alendronate Sodium | Alendronate Sodium | 63 | 18 |
| Alprazolam | Alprazolam | 60 | 12 |
| Ozempic | Semaglutide | 60 | 13 |
| Glipizide Er | Glipizide | 55 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 55 | 14 |
| Synthroid | Levothyroxine Sodium | 55 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 12 |
| Irbesartan | Irbesartan | 52 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 15 |
| Finasteride | Finasteride | 49 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 11 |
| Methocarbamol | Methocarbamol | 47 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 45 | 11 |
| Glimepiride | Glimepiride | 44 | 12 |
| Jardiance | Empagliflozin | 43 | suppressed |
| Prednisone | Prednisone | 42 | 26 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 33 |
| Clonazepam | Clonazepam | 39 | suppressed |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 37 | suppressed |
| Bupropion Xl | Bupropion Hcl | 36 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Pregabalin | Pregabalin | 30 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 21 |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 20 |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 21 | 14 |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Cartia Xt | Diltiazem Hcl | 11 | suppressed |
| Dupixent Syringe | Dupilumab | 11 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $302.67 · 13 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPVAXIVE, FARXIGA, GVOKE HYPOPEN, INGREZZA, Leqembi, MINIMED 780G, NURTEC ODT, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error